ClinicalTrials.Veeva

Menu
C

Chase Medical Research, LLC | Waterbury, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3298176
Tirzepatide
Retatrutide
Bapineuzumab
LY3437943
Finerenone
Orforglipron
Semaglutide
Linaclotide
Tolterodine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 101 total trials

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Not yet enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Not yet enrolling
Hypertension
Overweight or Obesity
Drug: Placebo
Drug: Orforglipron

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Not yet enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type...

Enrolling
Type 2 Diabetes (T2D)
Drug: Placebo (NNC0487-0111 oral)
Drug: NNC0487-0111 oral

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabet...

Enrolling
Obesity
Type 2 Diabetes
Drug: Tirzepatide
Drug: Placebo

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling
Seasonal Influenza
Biological: Fluarix Tetra
Biological: Fluarix®

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Active, not recruiting
Overweight
Obesity
Drug: Retatrutide
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Active, not recruiting
Obesity
Cardiovascular Diseases
Drug: Retatrutide
Drug: Placebo

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight a...

Active, not recruiting
Overweight
Obesity
Drug: Retatrutide
Drug: Placebo

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme dis...

Active, not recruiting
Lyme Disease
Biological: Placebo
Biological: mRNA-1975

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2...

Active, not recruiting
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: COMIRNATY®

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate

Trial sponsors

Lilly logo
Pfizer logo
Novo Nordisk logo
Bayer logo
Boehringer Ingelheim logo
Janssen (J&J Innovative Medicine) logo
MannKind logo
Moderna logo
AstraZeneca logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems